Journal Mobile Options
Table of Contents
Vol. 28, No. 5, 2009
Issue release date: December 2009
Dement Geriatr Cogn Disord 2009;28:449–454

Increase in the Oxidized/Total Coenzyme Q-10 Ratio in the Cerebrospinal Fluid of Alzheimer’s Disease Patients

Isobe C. · Abe T. · Terayama Y.
aDepartment of Neurology, Iwate Medical University, Morioka, and bDepartment of Neurology, Chitose Daiichi Hospital, Chitose, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background/Aim: The contribution of mitochondrial dysfunction and oxidative stress to the pathogenesis of Alzheimer’s disease (AD) has previously been described. We aimed to investigate whether the balance between the oxidized and reduced forms of coenzyme Q-10 (CoQ-10) is related to the pathogenesis of AD. Materials and Method: Thirty patients with AD (69.0 ± 4.1 years) and 30 healthy control subjects (63.8 ± 16.4 years) were enrolled in this study. Concentrations of oxidized CoQ-10 and reduced CoQ-10 were measured by high-performance liquid chromatography using an electrochemical detector. Results: The percentage of oxidized/total CoQ-10 in the cerebrospinal fluid (%CoQ-10, CSF) was significantly higher in the untreated AD group (78.2 ± 18.8%) than in the control group (41.3 ± 10.4%, p < 0.001), and there was a significant negative correlation between %CoQ-10 and the duration of the illness (rs = –0.93, p < 0.001). Conclusion: These findings in living AD patients suggest a possible role for %CoQ-10 in the pathogenesis of the early stage of AD development.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffa L, Haynes A, Irving N, James L: Segregation of missense mutation in the amyloid protein gene with familial Alzheimer’s disease. Nature 1991;349:704–706.
  2. Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, Bruder CE, Bohlooly YM, Gidlof S, Oldfors A, Wibon R, Tornell J, Jacobs HT, Larsson NG: Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004;429:417–423.
  3. Yasojima K, McGeer EG, McGeer PL: 3-Hydroxy-3-methylglutaryl-coenzyme A reductase mRNA in Alzheimer and control brain. Neurosci Lett 2001;297:97–100.
  4. Abe T, Tohgi H, Murata T, Isobe C, Sato C: Reduction in asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in the cerebrospinal fluid during aging and in patients with Alzheimer’s disease. Neurosci Lett 2001;312:177–179.
  5. Murakami Y, Ohsawa I, Kasahara T, Ohta S: Cytoprotective role of mitochondrial amyloid beta peptide-binding alcohol dehydrogenase against a cytotoxic aldehyde. Neurobiol Aging 2007;30:325–329.
  6. Ohta S, Ohsawa I: Dysfunction of mitochondria and oxidative stress in the pathogenesis of Alzheimer’s disease: on defects in the cytochrome c oxidase complex and aldehyde detoxification. J Alzheimers Dis 2006;99:155–166.
  7. Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, Caspersen C, Chen X, Pollak S, Chaney M, Trinchese F, Liu S, Gunn-Moore F, Lue LF, Walker DG, Kuppusamy P, Zewier ZL, Arancio O, Stem D, Yan SS, Wu H: ABAD directly links Abeta to mitochondrial toxicity in Alzheimer’s disease. Science 2004;304:448–452.
  8. Barberger-Gateau P, Letenneur L, Deschamps V, Peres K, Dartigues JF, Renaud S: Fish, meat, and risk of dementia: cohort study. BMJ 2002;325:932–933.
  9. Perry G, Castellani RJ, Smith MA, Harris PL, Kubat Z, Ghanbari K, Jones PK, Cordone G, Tabaton M, Wolozin B, Ghanbari H: Oxidative damage in the olfactory system in Alzheimer’s disease. Acta Neuropathol 2003;106:552–556.
  10. Yamamoto Y, Kawamura M, Tatsuno K: Formation of lipid hydroperoxides in the cupric ion-induced oxidation of plasma and low density lipoprotein; in Davies KJA (ed): Oxidative Damage and Repair. New York, Pergamon Press, 1991, pp 287–291.
  11. Yamamoto Y, Yamashita S: Plasma ratio of ubiquinol and ubiquinone as a marker of oxidative stress. Mol Aspects Med 1997;18:S79–S84.
  12. Jiménez-Jiménez FJ, Molina JA, de Bustos F, García-Redondo A, Gómez-Escalonilla C, Martínez-Salio A, Berbel A, Camacho A, Zurdo M, Barcenilla B, Enríquez de Salamanca R, Arenas J: Serum levels of coenzyme Q10 in patients with Parkinson’s disease. J Neural Transm 2000;107:177–181.
  13. de Bustos F, Molina JA, Jiménez-Jiménez FJ, Garcia-Rdondo A, Gomez-Escalonilla C, Porta-Etessam J, Berbel A, Zurdo M, Barcenilla B, Enriquez de Salamanca R, Arenas J: Serum levels of coenzyme Q10 in patients with Alzheimer’s disease. J Neural Transm 2000;107:233–239.
  14. Mariani C, Bresolin N, Farina E, Ferrante C, Clafaloni E, Sertorelli S, Ciccone A, Scarlato G: Muscle biopsy in Alzheimer’s disease: morphological and biochemical findings. Clin Neuropathol 1991;10:171–176.
  15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), ed 4. Washington, American Psychiatric Association, 1994, pp 135–155.
  16. Mckhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  17. Hachinski VC, Iliff LD, Zilhka E: Cerebral blood flow in dementia. Arch Neurol 1975;32:632–637.
  18. Folstein MF, Folstein SE, McHugh PR: ‘Mini-Mental State’. A practical method of grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  19. Isobe C, Murata T, Sato C, Terayama Y: Increased of oxidized/total coenzyme Q-10 ratio in cerebrospinal fluid in patients with Parkinson’s disease. J Clin Neurosci 2007;14:340–343.
  20. Murata T, Ohtsuka C, Terayama Y: Increased mitochondrial oxidative damage in patients with sporadic amyotrophic lateral sclerosis. J Neurol Sci 2008;15:66–69.

    External Resources

  21. Upston JM, Terentis AC, Stocker R: Tocopherol-mediated peroxidation of lipoproteins: implication for vitamin E as a potential antiatherogenic supplement. FASEB J 1999;13:977–994.
  22. Shults CW, Haas RH, Passov D, Beal MF: Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol 1997;42:261–264.
  23. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA: 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer’s disease. J Neurochem 1997;68:2092–2097.
  24. Murakami Y, Ohsawa I, Kasahara T, Ohta S: Cytoprotective role of mitochondrial amyloid beta peptide-binding alcohol dehydrogenase against a cytotoxic aldehyde. Neurobiol Aging 2009;30:325–329.
  25. Okamoto T, Fukui K, Nakamoto M, Kishi T, Okishio T, Yamagami T, Kanamori N, Kishi H, Hiraoka E: High-performance liquid chromatography of coenzyme Q-related compounds and its application to biological materials. J Chromatogr 1985;342:35–46
  26. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M; Parkinson Study Group: Effects of coenzyme Q10 in early Parkinson’s disease: evidence of slowing the functional decline. Arch Neurol 2002;59:1541–1550.
  27. Wadsworth TL, Bishop JA, Pappu AS, Woltjer RL, Quinn JF: Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer’s disease. J Alzheimers Dis 2008;14:225–234.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50